• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.

作者信息

Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P

机构信息

Arthritis Centre, Northwick Park Hospital, Harrow, Middlesex, AAI 30J, UK.

出版信息

Rheumatology (Oxford). 2005 Jul;44(7):939-47. doi: 10.1093/rheumatology/keh669. Epub 2005 May 18.

DOI:10.1093/rheumatology/keh669
PMID:15901904
Abstract
摘要

相似文献

1
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.英国风湿病学会关于成人强直性脊柱炎患者使用肿瘤坏死因子-α阻滞剂的处方指南。英国风湿病学会工作组报告
Rheumatology (Oxford). 2005 Jul;44(7):939-47. doi: 10.1093/rheumatology/keh669. Epub 2005 May 18.
2
[Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].[肿瘤坏死因子-α阻滞剂治疗期间的风险和副作用反应。一项免疫学分析]
Dtsch Med Wochenschr. 2004 Jul 23;129(30):1631-4. doi: 10.1055/s-2004-829005.
3
Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.在对英夫利昔单抗耐药或不耐受的强直性脊柱炎患者中，将治疗方案转换为每周一次给予50毫克依那西普：一项为期54周的研究结果
Arthritis Rheum. 2006 Oct 15;55(5):812-6. doi: 10.1002/art.22236.
4
Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.符合英国风湿病学会（BSR）强直性脊柱炎抗TNF指南的患者特征及治疗反应
Rheumatology (Oxford). 2007 Mar;46(3):439-41. doi: 10.1093/rheumatology/kel430. Epub 2007 Jan 25.
5
Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.强直性脊柱炎中的葡萄膜炎与肿瘤坏死因子阻断治疗
Ann Rheum Dis. 2008 May;67(5):729-30. doi: 10.1136/ard.2007.077370.
6
[Biological treatment of ankylosing spondylitis].
Ugeskr Laeger. 2008 Jun 9;170(24):2140-5.
7
Do TNF-blockers reduce or induce uveitis?
Rheumatology (Oxford). 2008 May;47(5):731-2. doi: 10.1093/rheumatology/ken091. Epub 2008 Mar 17.
8
Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.对脊柱关节炎患者进行肿瘤坏死因子α阻断治疗的评估。
Rheumatology (Oxford). 2005 Jan;44(1):17-23. doi: 10.1093/rheumatology/keh358. Epub 2004 Aug 24.
9
Multiple sclerosis following etanercept treatment for ankylosing spondylitis.使用依那西普治疗强直性脊柱炎后发生多发性硬化症。
Scand J Rheumatol. 2008 Sep-Oct;37(5):397-9. doi: 10.1080/03009740802136164.
10
Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.使用肿瘤坏死因子α拮抗剂治疗25例继发性淀粉样变性的风湿性炎症性疾病患者。
Am J Med. 2005 May;118(5):552-6. doi: 10.1016/j.amjmed.2005.01.028.

引用本文的文献

1
Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades.二十多年来强直性脊柱炎发病率、患病率和诊断时间的变化。
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001888.
2
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland.在芬兰，司库奇尤单抗与其他生物制剂相比治疗强直性脊柱炎的成本效益。
Clinicoecon Outcomes Res. 2019 Feb 15;11:159-168. doi: 10.2147/CEOR.S192235. eCollection 2019.
3
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.
在英国，司库奇尤单抗治疗活动性强直性脊柱炎的成本效果分析。
Pharmacoeconomics. 2018 Aug;36(8):1015-1027. doi: 10.1007/s40273-018-0675-9.
4
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.从英国医保支付方角度看戈利木单抗治疗强直性脊柱炎的成本效益
Rheumatol Ther. 2017 Dec;4(2):427-443. doi: 10.1007/s40744-017-0083-1. Epub 2017 Sep 27.
5
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.脊柱关节炎中抗TNF药物的准入标准：对1年比较性成本效益估计的影响
Cost Eff Resour Alloc. 2017 Sep 7;15:20. doi: 10.1186/s12962-017-0081-8. eCollection 2017.
6
Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.对总体人群健康和社会成本的影响，以及在强直性脊柱炎管理中纳入肿瘤坏死因子-α拮抗剂对实际成本效益的影响：一项动态人群建模研究。
Cost Eff Resour Alloc. 2015 Oct 7;13:18. doi: 10.1186/s12962-015-0044-x. eCollection 2015.
7
Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.在先前接受抗 TNFα 治疗时发生活动性结核病的类风湿关节炎或强直性脊柱炎患者中安全重新给予肿瘤坏死因子-α（TNFα）抑制剂。
J Korean Med Sci. 2014 Jan;29(1):38-42. doi: 10.3346/jkms.2014.29.1.38. Epub 2013 Dec 26.
8
Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.韩国接受肿瘤坏死因子拮抗剂治疗的患者中的分枝杆菌感染。
Lung. 2013 Oct;191(5):565-71. doi: 10.1007/s00408-013-9481-5. Epub 2013 Jun 1.
9
The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008.捷克共和国强直性脊柱炎的经济负担：2005 年与 2008 年的比较。
Rheumatol Int. 2013 Jul;33(7):1813-9. doi: 10.1007/s00296-012-2542-x. Epub 2013 Jan 13.
10
Compliance with NICE guidance on the use of anti-TNFalpha agents in ankylosing spondylitis: an east and west Midlands regional audit.遵循 NICE 指南在强直性脊柱炎中使用抗 TNF-α 药物的情况：东米德兰兹和西米德兰兹地区审计。
Clin Med (Lond). 2012 Aug;12(4):324-7. doi: 10.7861/clinmedicine.12-4-324.